|
|
| The 2018 OPPS final rule is one of the most controversial in recent years, with CMS finalizing a policy to drastically cut payments for drugs purchased under the 340B drug discount program by average sales price (ASP) minus 22.5% from the current ASP plus 6%. This policy will not only have a large financial impact on hospitals, but will also add potential regulatory burden, as providers will be required to report modifiers on separately payable drugs purchased through the program. During this program, expert speakers Jugna Shah, MPH, and Valerie A. Rinkle, MPA, will analyze the final rule and deliver a comprehensive program on how providers can prepare for the major changes coming in 2018, including how to assess the impact and implement changes related to 340B drug reporting. This program will cover: Payment reductions for the 340B drug discount program Drugs and facilities excepted from this policy CMS’ payment and informational modifiers for drugs that are part of the program Packaging policies Addition of low-level drug administration services Increased drug packaging threshold Billing and payment for laboratory services Modifications to current date of service policy Regulations for molecular pathology and advanced diagnostic laboratory tests Other key changes related to charging, coding, and billing outpatient services Inpatient-only list updates Chronic care management codes New APC for imaging without contrast Status indicator changes Major policies in the 2018 MPFS that impact outpatient hospital services Non-excepted, off-campus provider-based department payment Appropriate Use Criteria Medicare Diabetes Prevention Program | |
|
|